Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Shenhuang Granules for Sepsis
NCT06514339Phase 1Recruiting
- Sponsor
- First Affiliated Hospital, Zhejiang University School of Medicine
- Start
- Jul 2024
- Primary completion
- Mar 2026
- Modality
- HM (Herbal Medicine)
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of shenhuang granule in sepsis (2 arms), sponsored by First Affiliated Hospital, Zhejiang University School of Medicine. Primary endpoint: 28-day mortality rate. Started Jul 2024; status: recruiting.
02
Drugs
shenhuang granule
03
Conditions
sepsis
Beyond the preview
Go deeper on NCT06514339.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06514339.